Boston Scientific (BSX)
(Delayed Data from NYSE)
$98.98 USD
-0.90 (-0.90%)
Updated Sep 16, 2025 03:59 PM ET
2-Buy of 5 2
D Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BSX 98.98 -0.90(-0.90%)
Will BSX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BSX
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain Avanos Medical Stock in Your Portfolio Now
Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System
Cardinal Health Expands At-Home Solutions With New Texas Facility
Other News for BSX
BSX forms Lower Bollinger Band Walk on September 16
Noteworthy Tuesday Option Activity: BSX, FDX, PYPL
Is BSX heading for a slide? Fell Below 200 Day Moving Average shows up after sliding 2.77%
Interesting BSX Put And Call Options For January 2028
Boston Scientific’s Strong Growth Prospects and Strategic Initiatives Reinforce Buy Rating